Hikma Of Jordan Reaps Profits From Developments In Injectables Supply
This article was originally published in PharmAsia News
Executive Summary
Jordan's Hikma Pharmaceuticals reported a 49% increase in its injectable-drug business, primarily due to an 83% increase in U.S. sales.